Telix Pharmaceuticals advances prostate cancer treatment with successful TLX592 study

Telix Pharmaceuticals Limited (ASX: TLX) has announced the successful completion of the CUPID Phase I dose escalation study of TLX592, marking a significant advancement in ... Read More